Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.
about
Targeting the latent reservoir to achieve functional HIV cureEpigenetic control of HIV-1 post integration latency: implications for therapyControlling HIV-1: Non-Coding RNA Gene Therapy Approaches to a Functional CureImpact of Chromatin on HIV ReplicationManipulation of the host protein acetylation network by human immunodeficiency virus type 1Multi-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque ControllersTIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV InfectionHistone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytesAchieving HIV-1 Control through RNA-Directed Gene RegulationActivation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapyAntiretroviral therapy: Shifting sandsA Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes.Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines.The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1Replication competent virus as an important source of bias in HIV latency models utilizing single round viral constructs.Target engagement and drug residence time can be observed in living cells with BRET.Progress towards an HIV cure: update from the 2014 International AIDS Society SymposiumAutophagy induction by histone deacetylase inhibitors inhibits HIV type 1.A cell-based strategy to assess intrinsic inhibition efficiencies of HIV-1 reverse transcriptase inhibitors.Promoter Targeting RNAs: Unexpected Contributors to the Control of HIV-1 Transcription.Dynamics of HIV latency and reactivation in a primary CD4+ T cell model.Eradicating HIV-1 infection: seeking to clear a persistent pathogen.Immuno-modulatory strategies for reduction of HIV reservoir cells.Ex vivo response to histone deacetylase (HDAC) inhibitors of the HIV long terminal repeat (LTR) derived from HIV-infected patients on antiretroviral therapy.Abyssomicin 2 reactivates latent HIV-1 by a PKC- and HDAC-independent mechanism.Role of the macrophage in HIV-associated neurocognitive disorders and other comorbidities in patients on effective antiretroviral treatment.Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.The Depsipeptide Romidepsin Reverses HIV-1 Latency In VivoTargeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells.DYRK1A Controls HIV-1 Replication at a Transcriptional Level in an NFAT Dependent Manner.H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells.The need for treatment interruption studies and biomarker identification in the search for an HIV cure.HIV Integration Site Analysis of Cellular Models of HIV Latency with a Probe-Enriched Next-Generation Sequencing Assay.Leveraging Cancer Therapeutics for the HIV Cure Agenda: Current Status and Future DirectionsHuman Galectin-9 Is a Potent Mediator of HIV Transcription and ReactivationEx Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.The exclusion of people living with HIV (PLWH) from clinical trials in lymphoma.Histone Deacetylase Inhibitors Enhance CD4 T Cell Susceptibility to NK Cell Killing but Reduce NK Cell Function.BIRC2/cIAP1 Is a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency.Euphorbia Kansui Reactivates Latent HIV.
P2860
Q26745923-F6717C07-4BE8-422E-8E5E-A3D3FD97EE55Q26781191-0641FE7A-0620-40EB-B75B-F529C6FA8D97Q26781275-76B7E8DE-F684-4DA1-A1E2-D176ED44497CQ26782046-31DE0941-D2D1-464C-91FC-802A8C56B9BEQ26795463-CD4E2A29-CA63-4152-9F4F-ABE0221F35ECQ27312050-E5AC5F9D-BAD7-43D1-A7C7-536278C353F9Q27316403-584CA482-9D28-43C6-9979-308E6787D408Q27324527-1CB92C46-2E09-4D7C-B1C4-7F5FB7925AFFQ28080090-0D55D613-31E0-44E4-9F65-C996D548269EQ28544949-62383903-413C-4683-965F-B237FCC60489Q30384683-5B61D655-32E2-436E-8C18-CFCF09ACC54EQ30385378-08F4E013-C20F-4265-B526-282B9559727DQ30489412-3EBE0740-69C4-4668-BC1F-9094C7179C50Q33725916-5C80D6D7-06CE-4A40-A3CB-0986241F68DBQ34143903-AD19ED4F-405F-4F26-9493-03BDB755C4C5Q34503961-60445AA1-25B6-4696-A86C-0DA8CCB37F1AQ34869380-A533D1D0-9261-49D9-BEE8-DC31D0C9DC4BQ35103991-F58EF585-CF7B-4CD8-9192-C95D0443A0CDQ35105821-C1496A76-51D0-4C60-8C1E-7658B6093778Q35133922-055C0B0F-6860-4F23-B8DC-E173EC74CAEFQ35176166-CBF11919-92BE-431A-ADC5-E30DC1D66DF8Q35252186-B5F1D6FF-FB0A-43D6-BDB6-6F6239E7BA7DQ35329923-69315ABE-BABA-4BA0-9EFC-1C53197B8123Q35436367-39132A68-41AD-447E-80BF-73EE51D9FF54Q35538357-510774D0-15F4-4460-B289-A41C1830EB69Q35652578-B03F2371-E62C-4209-A6A0-5452274F6CBBQ35720063-2F09A329-0C6D-4E05-B4D4-B7D64C458FA0Q35778783-7881AC55-9668-4579-9178-73E01F6FCA20Q35833324-8D462E69-E87A-43A6-BD81-15A783A756B9Q35862378-645DB6B4-65A3-4375-8908-85788C1A0462Q35914266-3D2C67F0-3587-4097-A792-6F9CC5D0DDB0Q35928987-1610AEF9-2B9A-47BA-935D-94E91E0FF93DQ35935136-5639542F-60E5-49C7-A5B4-65383D90EBDBQ36030989-82ED3AE2-9F69-4FBE-87ED-BA66927494B2Q36037844-5BA25A78-7696-45B7-97AF-B544AEBF45E5Q36076018-C652542C-74B1-4817-806F-22C876572254Q36081411-B73B1515-9245-469A-9878-7115DB67B1CDQ36104946-D1E8F5E5-8C6E-40B0-BCA4-A53CC6184F11Q36198250-0A746439-31B1-416B-AA89-CC92645FD2CFQ36224979-AC473731-BF25-4BC4-841F-13FFE261B6C1
P2860
Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Histone deacetylase inhibitor ...... ns achieved by clinical dosing
@nl
Histone deacetylase inhibitor ...... s achieved by clinical dosing.
@ast
Histone deacetylase inhibitor ...... s achieved by clinical dosing.
@en
type
label
Histone deacetylase inhibitor ...... ns achieved by clinical dosing
@nl
Histone deacetylase inhibitor ...... s achieved by clinical dosing.
@ast
Histone deacetylase inhibitor ...... s achieved by clinical dosing.
@en
prefLabel
Histone deacetylase inhibitor ...... ns achieved by clinical dosing
@nl
Histone deacetylase inhibitor ...... s achieved by clinical dosing.
@ast
Histone deacetylase inhibitor ...... s achieved by clinical dosing.
@en
P2093
P2860
P50
P3181
P1433
P1476
Histone deacetylase inhibitor ...... s achieved by clinical dosing.
@en
P2093
Alivelu Irrinki
Angela Tsai
Celsa A Spina
Datsen George Wei
Deborah McMahon
Derek Sloan
Elizabeth Fyne
George Stepan
Jacob Lalezari
P2860
P304
P3181
P356
10.1371/JOURNAL.PPAT.1004071
P407
P577
2014-04-10T00:00:00Z